Evidence Hub

Evaluation of [18F]N-methyl-lansoprazole as a tau PET imaging agent in first-in-human studies

V. Kramer, Allen F. Brooks, Arlette Haeger, R. Kuljiš, W. Rafique, R. Koeppe, D. Raffel, K. Frey et al.

ACS Chemical Neuroscience, 2020

15 participants · 25 citations

Abstract

Development of positron emission tomography (PET) imaging agents capable of quantifying tau aggregates in neurodegenerative disorders such as Alzheimer’s disease (AD) is of enormous importance in the field of dementia research. The aim of the present study was to conduct first-in-man imaging studies with the potential novel tau imaging agent [18F]N-methyl lansoprazole ([18F]NML). Herein we report validation of the synthesis of [18F]NML for clinical use by labeling the trifluoromethyl group via radiofluorination of the corresponding gem-difluoro enol ether precursor. This is the first use of this method for clinical production of PET radiotracers, and confirmed that it can be readily implemented at multiple production facilities to provide [18F]NML in good non-corrected radiochemical yield (3.4 ± 1.5 GBq, 4.6 ± 2.6%) and molar activity (120.1 ± 186.3 GBq/μmol), excellent radiochemical purity (>97%), and suitable for human use (n = 15). With [18F]NML in hand, we conducted rodent biodistribution, estimates of human dosimetry, and preliminary evaluation of [18F]NML in human subjects at two imaging sites. Healthy controls (n = 4) and mild cognitively impaired (MCI) / AD patients (n = 6) received [18F]NML (tau), [18F]AV1451 (tau) and [18F]florbetaben or [18F]florbetapir (amyloid) PET scans. A single progressive supranuclear palsy (PSP) patient also received [18F]NML and [18F]AV1451 PET scans. [18F]NML showed good brain uptake, reasonable pharmacokinetics and appropriate imaging…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free